Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

John L. Marshall, MD
Published: Monday, Dec 04, 2017



John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

RAS signaling is very important for many GI cancers, but it is very complicated, says Marshall. There may be new treatments on the horizon, though, said Frank McCormick, PhD, FRS, who oversees the nation’s strategic initiative to develop RAS inhibitors.

If an effective RAS inhibitor is developed, it could revolutionize the treatment of GI cancer, says Marshall.
 


John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

RAS signaling is very important for many GI cancers, but it is very complicated, says Marshall. There may be new treatments on the horizon, though, said Frank McCormick, PhD, FRS, who oversees the nation’s strategic initiative to develop RAS inhibitors.

If an effective RAS inhibitor is developed, it could revolutionize the treatment of GI cancer, says Marshall.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x